摘要
复方依折麦布瑞舒伐他汀钙片是一种新型调血脂药物,通过胆固醇吸收抑制剂依折麦布与选择性的HMGCoA还原酶抑制剂瑞舒伐他汀钙形成固定剂量的单片复方制剂,作用机理互补,可满足单方制剂临床未被满足的需求。本文就复方依折麦布瑞舒伐他汀钙片现有质量研究进行综述,并进行分析总结,为该复方制剂质量控制提供理论依据。
Compound ezetimibe and rosuvastatin calcium tablet is a new type of blood lipid regulating drug. It is a fixed dose single tablet compound preparation through cholesterol absorption inhibitor ezetimibe and selective HMG-CoA reductase inhibitor rosuvastatin calcium. The mechanisms of action of the two components are complementary, which can meet the clinical unmet needs of single formulation. In this paper, the existing quality studies of compound ezetimibe and rosuvastatin calcium tablets were reviewed and analyzed to provide a theoretical basis for the quality control of the compound preparation.
作者
张玲
张锐武
奚兴苹
李金虹
陈彤
张伟
ZHANG Ling;ZHANG Ruiwu;XI Xingping;LI Jinhong;CHEN Tong;ZHANG Wei(School of Pharmacy and Yunnan Key Laboratory of Pharmacology for Natural Medicines,Kunming Medical University,Kunming 650500,China;Yunnan Longjin Kangyou Biomedical Company,Kunming 650503,China;Kunming Longjin Pharmaceutical Company,Kunming,Yunnan 650503,China)
出处
《广东药科大学学报》
CAS
2023年第1期153-158,共6页
Journal of Guangdong Pharmaceutical University
基金
云南省高端仿制药研发创新平台建设及产业化应用示范(202202AH210003)。
